Rein Therapeutics (RNTX) Proxy Filing summary

Executive summary

• Annual meeting of stockholders was adjourned due to lack of quorum and will reconvene on July 23, 2025 at 9:00 a.m. Eastern Time.

• No changes have been made to the proposals to be voted on; the record date remains May 5, 2025.

• Stockholders are encouraged to vote by July 22, 2025, and previously submitted proxies remain valid unless revoked.

• Lead product candidate LTI-03 is in Phase 2 trials for idiopathic pulmonary fibrosis; LTI-01 has completed Phase 1b and 2a trials for loculated pleural effusions.

• Both product candidates have received Orphan Drug Designation, with LTI-01 also receiving Fast Track Designation in the U.S. and E.U.

Voting matters and shareholder proposals

• All proposals described in the definitive proxy statement remain unchanged for the reconvened meeting.

• Board of directors recommends voting "FOR" each proposal.

• Proxies previously submitted will be counted unless revoked or changed before the meeting.

Board of directors and corporate governance

• Board encourages all eligible stockholders to participate and vote in the adjourned annual meeting.